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Summary 
Estradiol-treated, rat pituitary cells were studied to examine the effects of progesterone (P) on follicle-stimulat- 
ing hormone (FSH) synthesis and secretion. Progesterone was administered prior to or concurrent with 3 h secretory 
challenges with either gonadotropin-releasing hormone (GnRH), the iontophore A23187, the protein kinase C 
activator phorbol 12,13-myristate (PMA), or no secretagogue. Medium FSH levels and cell FSH stores were 
quantified by radioimmunoassay and bioassay. Acute ( < 6 h) exposures to P increased medium levels of immunore- 
active and bioactive FSH following GnRH challenge without influencing total (cell + medium) values whereas 
chronic (9-24 h) treatments increased both parameters. Chronic P elevated total FSH levels even when no 
secretagogue was present. 
Studies with antiprogestins, Sa-dihydroprogesterone and Sa-reductase inhibitors revealed that this direct action 
of P depended on progestin receptor occupation but not on 5c-u-reduction. These studies indicate that P selectively 
increases bioactive and immunoactive FSH levels, presumably by increasing FSH synthesis, and characterize the 
time course and cellular mechanisms of this response. To accommodate for P modulation of total FSH levels, FSH 
secretion was standardized as the percentage of cellular stores available for release. Progesterone modulation of 
GnRH-stimulated FSH secretion was multiphasic, i.e. increased at O-6 h, unchanged at 9 h and suppressed at 24 h. 
Acute and chronic exposures to P similarly modulated A23187-stimulated FSH release, whereas both P treatments 
increased PMA-stimulated FSH secretion. In these experiments P modulated luteinizing hormone secretion in 
parallel fashion, suggesting that common cellular mechanisms underlie peptidergic and steroidal regulation of the 
secretion of both gonadotropins. 
Introduction 
Our understanding of the cellular mechanisms un- 
derlying progesterone (PI regulation of rat go- 
nadotroph function in vitro has been derived primarily 
from studies on luteinizing hormone (LH) synthesis 
and secretion (Hsueh et al., 1979; Lagace et al., 1980; 
Tang, 1980; Drouin and Labrie, 1981; Turgeon and 
Waring, 1981, 1983, 1990; Kiesel et al., 1987; Ortmann 
et al., 1989; Krey and Kamel, 1990a,b; Krey et al., 
1990). Only Labrie and his coworkers have examined 
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the temporal characteristics of P modulation of 
follicle-stimulating hormone (FSH) by estrogen-treated 
gonadotrophs, noting that acute (< 6 h) and chronic 
(2 24 h) pretreatments increase the level of FSH se- 
creted into the medium in response to gonadotropin- 
releasing hormone (GnRH; Drouin and Labrie, 1980; 
Lagace et al., 1980). This latter observation is unusual 
since chronic P dramatically suppresses LH secretion. 
However, Drouin and Labrie (1981) also reported that 
chronic exposures to P increased total (cell + medium) 
FSH levels without influencing total LH levels. Re- 
cently, we confirmed that a 24 h treatment with P prior 
to GnRH challenge increases FSH and suppresses LH 
levels in medium and selectively increases cell stores of 
FSH available for release (Krey and Kamel, 1990~). 
However, when we accounted for the changes in cell 
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levels by calculating secretion as gonadotropin released 
in medium/total gonadotropin available for release, 
we observed declines in the secretion of both hor- 
mones, suggesting that chronic P treatment suppresses 
all secretory responses to GnRH. We now extend this 
observation by characterizing several aspects of P con- 
trol of FSH synthesis and secretion: describing the 
temporal parameters of P modulation of FSH secretion 
stimulated by GnRH, the Ca2+ iontophore A23187 
and a phorbol ester; examining the influences of P on 
FSH bioactivity; and analyzing the intracellular mecha- 
nisms involving P processing and the expression of its 
actions. 
Materials and methods 
Anterior pituitary glands were collected from female 
Sprague-Dawley rats (Charles River Labs, Kingston, 
NY, USA; Taconic Farms, Germantown, NY, USA), 
dispersed enzymatically to single cell preparations, and 
plated at 4.5-5 X 10’ cells/35 mm culture dish con- 
taining 1.5 ml of Dulbecco’s modified Eagle’s medium 
containing 1% non-essential amino acids, 25 mM 
Hepes, 100 Fg/ml streptomycin sulfate, 100 U/ml 
penicillin G and 10% and 2.5% dextran + charcoal- 
stripped horse and fetal calf serum (DMEMS). The 
procedures and reagents used to disperse and culture 
the cells have been described (Krey and Kamel, 1990a). 
Estradiol (E,), P and 5a-pregnan-3,20-dione (5a- 
DHP) were purchased from Steraloids (Wilton, NH, 
USA); the synthetic progestin RU5020 and antipro- 
gestin RU486 were provided by Roussel (Romaineville, 
France). Flutamide was supplied by Schering (Bloom- 
field, NJ, USA); the Sa-reductase inhibitor 17P-N,N- 
diethylcarbamoyl-4-methyl-4-aza-5~-androstan-3-one 
(4MA) was the gift of Dr. G.H. Rasmussen (Merck, 
Sharp and Dohme, Rahway, NJ, USA). Steroids were 
diluted in ethanol and added to media at 1 : 100- 
1: 10,000. Synthetic GnRH was purchased from Beck- 
man Instruments (Palo Alto, CA, USA) and Cal- 
biochem (LaJolla, CA, USA), diluted in saline at lo-” 
M and stored frozen at - 20°C until use. A23 187 and 
phorbol 12-myristate 13-acetate (PMA) were pur- 
chased from Sigma (St. Louis, MO, USA), diluted in 
dimethyl sulfoxide to 10-2-10p” M and stored at 
- 20°C. 
The experimental design has been described previ- 
ously (Krey and Kamel, 1990a,b; Krey et al., 1990) and 
resembles that of Lagace and coworkers (1980). At 72 
h after culture in 90% air: 10% CO,, medium was 
collected and replaced with 1.5 ml DMEMS containing 
lo-” M E,. Secretory challenges were initiated 48 h 
later. Progesterone (lo-’ M), a concentration which 
closely approximates the periovulatory levels in the 
circulation of rats (Freeman et al., 19751, was added at 
varying time periods prior to and/or concurrently with 
the secretagogue. In some studies the P stimulus was 
‘interrupted’ - medium was removed and the cells 
washed 4 X with 1.5 ml DMEM prior to replacement 
with DMEMS + E, + P. 
Secretory challenges consisted of two washes with 
1.5 ml DMEM and exposure to 1.5 ml DMEM contain- 
ing E, k P, 1 mM bacitracin (Sigma, St. Louis, MO, 
USA) and the appropriate secretagogue. Medium was 
collected 1, 2 or 3 h later and stored at -20°C. 
Cellular gonadotropin stores were quantified post-chal- 
lenge in cultures lysed by freezing-thawing twice in 1.5 
ml buffer (150 mM NaCl, 50 mM Tris and 5 mM 
EDTA, pH 7.4; Keel and Grotjan, 1985) containing 100 
FS%,,,,m FSHtotsl X FSHralsased 
H 
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Fig. 1. Influences of different progesterone (P) treatments on GnRH-stimulated LH and FSH secretion by pituitary cell cultures. The cells were 
exposed to E, (10W9 M) for 48 h prior to a 3 h challenge with GnRH (3 X lo-” M). Progesterone (IO-’ M) was added either concurrently with 
(PO) or 3 or 24 h prior to GnRH. Gonadotropin levels were quantified in medium and cell (total = medium+cell) and percent gonadotropin 
release calculated (medium/total). Data are standardized as P-induced changes relative to E,-treated control cells in three different cultures. 
* p < 0.005 vs. E, control (ANOVA and Bonferroni’s t-test). 
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TABLE 1 
INFLUENCES OF ACUTE (2 hl AND CHRONIC (24 h) EXPOSURES TO P ON GnRH-STIMULATED LH AND FSH SECRETION AND 
THEIR TOTAL (MEDIUM + CELL) LEVELS 
Cultures were harvested at 1, 2 and 3 h after GnRH (3 X lo-” M) treatment. 
Time LH (pg RP, /culture) FSH (ng RP, /culture) 
Medium Total % released Medium Total % released 
E2 lh 2.lkO.l * 11.2*0.1 18.9+0.8 5.8+0.2 19.2k 1.2 30.5 f 0.9 
E2 +P2h 3.5kO.2 ** 11.3kO.6 31.2+3.1 ** 8.2+0.5 ** 24.1 + 1.3 33.9* 1.4 
E2 +p2,h 1.3kO.l ** 10.6 + 0.5 12.2kO.6 ** 8.5kO.3 ** 38.7k1.3 ** 22.0 + 0.3 * * 
E2 2h 5.5 kO.4 11.3+ 1.2 48.6 f 2.1 10.9*0.1 22.0* 1.4 50.0 f 3.3 
E2 + ‘2, 7.4kO.9 ** 11.6+ 1.0 64.Ok2.5 ** 13.7kO.2 ** 25.8k 1.6 53.4 * 3.0 
E, +P24h 2.3+0.2 ** 8.7kO.4 27.0k2.1 ** 13.7+0.1 ** 42.5 + 0.8 * * 32.3 f 0.3 * * 
E2 3h 5.5 +0.2 9.5 k 0.6 57.9 k 1.8 10.8 & 0.7 21.0+ 1.7 51.7* 1.1 
E2 +‘2h 7.6kO.6 ** 10.5 + 0.4 71.6k2.3 ** 16.9kO.5 ** 26.7 k 0.4 63.2+2.3 ** 
Ez +Pz,t, 3.OkO.4 ** 8.8 i 0.6 33.7 + 2.4 * * 18.7k1.4 ** 43.1 k2.1 ** 43.2+ 1.3 ** 
* Mean + SEM (n = 4). 
** p < 0.05 vs. E, control (ANOVA and Dunnett’s test). This experiment has been replicated in three other cell preparations with similar 
results. 
III/ml Trasylol (FBA Pharmaceuticals, New York, NY, 
USA). 
LH and FSH levels in medium and cell lysate sam- 
ples were quantified by radioimmunoassay. The LH 
system utilized antiserum to oLH (GDN No. 15) and 
has been described (Krey and Kamel, 1990a). The FSH 
assay utilized reagents from the NIDDK kit: anti- 
rFSHS,, as antibody, [‘251]rFSH16 as tracer and 
rFSHRP, or rFSH1, as standard. Intraassay coefficient 
of variation averaged 10%. FSH bioactivity was as- 
sessed by a rat Sertoli cell bioassay using rFSH1, as 
standard (Padmanabhan et al., 1988). Assay sensitivity 
was 0.1 ng rFSHI,/tube; intraassay coefficient of vari- 
ation was < 12.5%. Every sample from each experi- 
ment was run simultaneously in both assays. 
Studies were routinely repeated in three or more 
different cell preparations; individual experiments were 
performed in triplicate or quadruplicate. Dose-re- 
sponse curves were run for GnRH (10-“-10-7 M), 
and curve parameters were calculated according to 
Rodbard et al. (1977) and tested for statistical differ- 
ences between steroid treatments by analysis of vari- 
ance for repeated measures and then dependent t-tests. 
In the other experiments, data were subjected to two- 
way analyses of variance using cell culture replication 
as a variable. Within- and among-group comparisons 
were made by analyzing the simple main effects; post- 
hoc comparisons were made with Dunnett’s test or 
Bonferroni’s t-test. To minimize the impact of culture- 
to-culture variation in secretion and cell levels, some 
data has been standardized as percentage change rela- 
tive to E, controls prior to presentation. 
Results 
Medium FSH levels secreted by cells exposed to P 
acutely ( < 6 h) and chronically (24 h) were consistently 
elevated above those of E,-treated controls regardless 
of the size or duration of the GnRH challenge (Fig. 1; 
Tables 1 and 2). However, whereas acute exposure to P 
also elevated medium LH levels, chronic P exposure 
suppressed them. The influences of P on medium FSH 
levels were consistently characterized by increases in 
basal or maximal values but could not be attributed to 
any significant change in ED,, for GnRH (Table 2). 
When cellular gonadotropins were quantified, total 
(cell + medium) FSH levels did not change following 
acute P but increased significantly within 24 h; there 
were no comparable changes in total LH (Fig. 1; Table 
TABLE 2 
INFLUENCES OF ACUTE (3 hl AND CHRONIC (24 h) EXPO- 
SURE TO P (lo-’ M) ON PARAMETERS OF THE GnRH 
DOSE-RESPONSE CURVE FOR FSH SECRETION AS DE- 
TERMINED BY ANALYSES OF MEDIUM FSH VALUES 
Cell preparation 
1 2 3 4 5 
A: Minimum (ng rFSHRP, /ml) 
J52 4.3 7.2 3.3 5.2 1.7 
E, + Pacute * 5.4 10.8 _ 6.8 4.1 
EZ + Pchronic * * 6.1 10.8 4.6 7.1 3.7 
B: Maximum (ng rFSHRP, /ml) 
E2 13.7 27.1 7.3 10.3 11.6 
E2 + Pacute * 15.7 29.8 - 12.7 17.5 
EZ + Pchronic * 15.9 29.7 11.7 13.1 22.0 
C: ED,, (1O-9 M) 
J32 0.61 2.56 1.42 0.41 0.79 
E2 + Pacute 0.52 2.08 - 0.54 0.95 
E2 + Pchronic 0.93 2.03 2.24 1.63 3.01 
* p < 0.05 vs. E, (ANOVA for repeated measures; dependent 
t-test). 
** p < 0.01 vs. E, (ANOVA for repeated measures; dependent 
t-test). 
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Fig. 2. Influences of different progesterone (PI treatments on PMA- 
stimulated LH and FSH secretion by pituitary cell cultures. Data are 
standardized as P-induced changes relative to E,-treated control 
cells in seven different cultures. * p < 0.005 vs. E, control (ANOVA 
and Bonferroni’s t-test). 
1). To accommodate for this variability in releasable 
gonadotropin stores, FSH (and LH) secretion was cal- 
culated as a percentage of the FSH (LH) stores avail- 
able for release. These parameters displayed parallel 
biphasic patterns, being elevated with Pacute and sup- 
pressed with Pchronic treatment. FSH and LH secretion 
progressively increased throughout the 3 h GnRH chal- 
lenge but consistently reflected the modulatory actions 
Of ‘a,~,, and Pchronic treatments (Table 1). 
The selective action of Pchronic to increase total FSH 
was consistently observed with no secretagogue or when 
A23187 (10e5 M) and PMA (10e7 Ml were used. In 
the absence of secretagogue, Pchronic significantly in- 
creased total FSH over estrogen-treated controls by 
142+ 7% (mean + SEM, n = 6, p < 0.005) as com- 
pared to 149 f 6% if the same cell preparations were 
challenged with 3 x lo- ” M GnRH. In three other 
cell preparations cotreated with GnRH, A23187 and 
PMAy Pchronic increased total FSH by 124 k 4%, 140 f 
4% and 130 k 8%, respectively, over E,-treated con- 
trols; each increase was significant (p < 0.051. 




Fig. 3. Influences of the antiprogestin RU486, the antiandrogen 
flutamide and the 5a-reductase inhibitor 4MA on P-induced in- 
creases in total (medium + cell) FSH levels. P (10-s Ml was added 24 
h prior to a 3 h challenge with GnRH; lOO-fold molar excesses of the 
other compounds were added 1 h prior to P. * p < 0.05 vs. appropri- 
ate no-P control (t-test); similar results were noted in three other cell 
preparations. 
Progesterone modulation of A23187-stimulated FSH 
secretion depended on the percentage of cellular hor- 
mone released. When the iontophore released less 
than 50% of cell stores in E,-treated controls, a secre- 
tion level routinely observed with the GnRH chal- 
lenges, ‘xu,, and Pchronic significantly (p < 0.05) en- 
hanced (129 + 7%, n = 41 and suppressed (86 h 9%) 
FSH release relative to E,-treated controls. However, 
in those cultures in which A23187 stimulated the re- 
lease of 2 65% of cell stores, FSH secretion was not 
increased by Pacute treatment (97 + 3%, n = 4), but was 
suppressed significantly (80 f 5%, p < 0.05) by Pchronic. 
Significantly, the LH secretion pattern paralleled that 
for FSH in each A23187-treated culture. In marked 
contrast to the patterns obtained for GnRH and 
A23187, both P,,,,, and Pchronic treatments increased 
PMA-stimulated FSH and LH secretion (Fig. 2). 
A second series of experiments examined the intra- 
cellular processing of P underlying the increase in total 
TABLE 3 
INFLUENCES OF CHRONIC EXPOSURES TO Sa-DIHYDROPROGESTERONE (5~DHP) AND PROGESTERONE (P) ON TOTAL 
(MEDIUM + CELL) FSH LEVELS IN Ez-TREATED PITUITARY CELL CULTURES 
Treatment Total FSH (ng rFSHRP, /culture) 
Cell preparation 
1 2 3 
E2 25.4& 1.7 * 21.7+0.8 34.1 f 2.9 
E,+P(lO-‘M) 33.0 f 0.5 41.0+5.0 45.9k2.1 
E, + Sa-DHP (lo-’ Ml 29.3 f 1.0 34.Ok4.0 31.8+2.2 
* Mean * SEM (n = 3). 
p < 0.005, E, vs. E, + P; p < 0.01, E, vs. E, +5a-DHP (ANOVA and Bonferroni’s t-test). 
4 5 
22.2 * 0.5 14.8k0.8 
25.5 & 0.8 20.1 f 1.3 
21.3+ 1.0 21.2* 1.0 
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TABLE 4 
INFLUENCES OF DIFFERENT PROGESTERONE (P) TREATMENTS ON TOTAL (MEDIUM + CELL) FSH LEVELS IN E,-TREATED 
PITUITARY CELL CULTURES 
Treatment Total FSH (ng rFSHRP, /culture) 
Cell preparation 
1 2 3 
A: P (lo-’ M) for 6 h immediately prior to GnRH challenge 
E2 17.6+- 1.0 * 25.8+ 1.5 9.6+ 1.6 
E,+P 21.7f 1.0 31.1 f 1.9 18.4k3.0 
B: P (lo-’ MI for 6 h beginning at 24 h prior to GnRH challenge 
E2 9.0+ 1.0 19.1+1.3 24.9 + 0.8 
E,+P 14.6+0.5 20.4 + 0.4 30.4 + 1.8 
4 5 6 
20.2* 1.3 23.5 f 2.9 24.2 + 7.0 
27.9k3.9 31.6+3.5 23.9+ 1.2 
20.2 + 1.3 23.5 + 2.9 24.2 k 2.0 
28.4+ 1.8 27.1+ 2.4 28.0 f 2.9 
* Mean+SEM (n = 3). 
p < 0.005, E, vs. E, + P for both 6 h P treatments (ANOVA). 
FSH in E,-treated cells. Significantly, cotreatment with 
RU486 blocked the FSH response whereas the antian- 
drogen flutamide had no effect (Fig. 3). Cotreatment 
with a lOO-fold molar excess of 4MA also failed to 
block P’s action on total FSH levels (Fig. 31, suggesting 
that Sa-reduction of P was not necessary. This hypoth- 
esis was supported further by observations that Scz-DHP 
did not elevate total FSH levels more effectively than 
did P (121 + 13% vs. 141 _t 13%, respectively; Table 3) 
and that RU5020, a synthetic progestin not subjected 
to Sa-reduction, was as effective as P (data not shown). 
In time-course studies, a 9 h exposure to P (6 h 
pretreatment + 3 h cotreatment with GnRH) was suffi- 
cient to increase total FSH levels (Table 4). In contrast, 
6 h of exposure (3 h pretreatment + 3 h cotreatment 
with GnRH) did not elevate total FSH levels (Fig. 1). 
However, 6 h P treatments did elevate total FSH when 
the levels were monitored 18 h after terminating the 
exposure to P (Table 4). Such ‘interrupted’ P treat- 
ments produced greater elevations in total FSH when 
longer exposures to P or shorter termination intervals 
were studied (data not shown). 
In a final series of experiments medium and cell 
FSH levels were quantified by radioimmunoassay and 
bioassay. PaCut, and Pchronic treatments produced signifi- 
cant changes in FSH bioactivity that were similar to 
TABLE 5 
INFLUENCES OF ACUTE (2 h) AND CHRONIC (24 h) EXPOSURE TO P ON GnRH-STIMULATED IMMUNOREACTIVE AND 
BIOACTIVE FSH (FSH imm AND FSH,io, RESPECTIVELY) SECRETION INTO MEDIUM AND THEIR TOTAL (CELL+MEDIUM) 
LEVELS. THE B : I RATIOS FOR SECRETED FSH ARE ALSO PRESENTED 
The four different culture preparations were exposed to GnRH (3 X lo-” MI for 3 h. 
Treatment Preparation Medium FSH 
(ng rFSH1 7 /ml) 
FSH imm FSHb, 
B:I Total FSH 
(ng rFSH1 7 /ml) 
FSHimm FSH bio 
E2 1 2.9kO.l * 
E2 + Pa,,,, 4.1 kO.2 
EZ + Pchronic 4.6kO.7 
E2 
E2 + Pm,, 
EZ + Pchronic 




E2 + Pacute 
EZ + Pchronic 




E2 + Pacute 
EZ + Pchronic 
4 4.5 * 0.5 
7.5 & 0.3 









2.9 f 0.2 
2.2kO.l 
4.0f0.8 
2.5 f 0.3 
0.48 + 0.03 
0.36 + 0.08 
0.31 f 0.08 
0.27 f 0.06 
0.27 f 0.01 
0.27 + 0.04 
0.41 f 0.03 
0.40 
0.50 f 0.05 
0.51+ 0.08 
0.54*0.10 
0.50 f 0.08 
14.5 f 0.9 
14.2kO.9 
24.8 f 2.3 
17.1 f 2.5 
29.0 f 2.8 
41.0* 3.6 

















41.0 + 10.9 
* Mean f SEM (n = 3). 
p < 0.01, E, vs. E, + P,,,,, and E, + Pchronic for medium FSHimm and FSH bio (ANOVA and Bonferroni’s f-test). 
p < 0.01, E, vs. E, + Pchronic for total FSHimm and FSHbi, (ANOVA and Bonferroni’s t-test). 
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those noted for FSH immunoactivity (Table 5). How- 
ever, there was no significant change in B:I for either 
the FSH secreted into the medium (Table 5) or re- 
tained in the cells (data not shown). 
Discussion 
The present studies on FSH secretion further illus- 
trate that periovulatory concentrations of P influence 
gonadotropin synthesis, storage and secretion by a di- 
rect action on gonadotrophs. The dramatic effect of 
P chronic treatments on cell FSH stores diverges markedly 
from previous observations for LH and suggests a 
direct and selective activation of FSH synthesis. In 
contrast, Pacut, and Pchronic treatments modulate secre- 
tagogue-induced LH and FSH secretion in similar fash- 
ion, most likely via a common cellular mechanism(s). 
These progestational influences on FSH synthesis and 
secretion may play an important role in determining 
the temporal and quantitative aspects of periovulatory 
FSH secretion during the rat estrous cycle. 
Our findings, like those of Drouin and Labrie (19811, 
indicate that Pchronic selectively increases cellular FSH 
stores in E,- and GnRH-treated rat pituitary cell cul- 
tures. Moreover, we report similarly sized increases 
with A23187 or PMA, or even in the absence of a 
secretagogue. This last observation conclusively 
demonstrates that this response is to a direct action of 
P on the gonadotroph. Significantly, chronic testos- 
terone (T) also selectively increases total FSH levels in 
non-E,-treated cells (Drouin and Labrie, 1976; 
Kennedy and Chappel, 1985; Krey and Kamel, 1991). 
In this regard, it is relevant that progestin and andro- 
gen receptors are primarily localized in gonadotrophs 
(DuBois et al., 1978; Sar and Stumpf, 1978, 1979; 
Thieulant and Duvall, 1985; Fox et al., 1990). More- 
over, the present results with P and RU486 (Fig. 3) and 
the results of similarly designed studies with T and 
flutamide (Krey, unpublished observations) indicate 
that occupation of these receptors is necessary for the 
appropriate increases in FSH stores. In 1981 Drouin 
and Labrie reported that P increases cell FSH stores in 
non-E,-treated cell cultures, cultures presumably de- 
void of progestin receptors (Krey et al., 1990). Perhaps, 
under these experimental circumstances, P (lop7 M) 
elevates cell FSH levels by interacting with resident 
androgen receptors (Handa et al., 1987). 
In contrast to the importance of progestin receptors, 
Sa-reductase activity does not appear to play an essen- 
tial role in P actions on FSH, even though this enzyme 
has been proposed to be important in androgen and 
progestin regulation of gonadotroph function (Denef et 
al., 1980; Martini, 1982). Such a conclusion is based on 
the observations that non-reducible progestins effec- 
tively increase cell FSH levels whereas Sa-DHP is, if 
anything, slightly less effective than P and that 4MA, at 
molar excesses sufficient to.block Sa-reduction in these 
cell cultures (Liang et al., 1983, 1984; Kamel and Krey, 
19911, fails to influence P- or T-induced elevations in 
total FSH (Fig. 3; Kamel and Krey, 1991). 
The importance of progestin receptor occupation 
suggests that P works through a genomic mechanism to 
increase cell FSH stores. Such a hypothesis is also 
suggested by the 2 6 h interval before FSH stores rise 
and the retention of this increase for up to 18 h 
following P withdrawal. Although we have not tested 
whether FSH synthesis actually increases by quantify- 
ing FSH subunit mRNA levels in these cells, Attardi 
and Fitzgerald (1990) have recently demonstrated that 
P significantly elevates FSHP mRNA within 5-8 h in 
immature, estrogen-treated, female rats. Curiously, 
however, these changes were not accompanied by any 
alteration in cell FSH stores or secretion rate. Gharib 
and coworkers (1990) also reported that 6-12 h also 
transpires before T elevates FSHP mRNA levels in rat 
pituitary cell cultures. 
The findings that Pchronic selectively increases cell 
FSH levels contrast dramatically with the reports of 
Miller and his coworkers that P treatment only sup- 
presses FSH synthesis by cultures of sheep pituitary 
cells (Batra and Miller, 1985; Phillips et al., 1988). 
Moreover, whereas P’s actions on FSH depend on 
estrogen pretreatment in rat cells, such a pretreatment 
is not necessary in sheep cells. It is unlikely that 
differences in steroid administration can explain these 
differences since physiologic concentrations of P were 
used in both studies and Miller and his coworkers 
consistently noted P-induced suppression after short- 
term (3-24 h) treatments. Significantly, acute expo- 
sures to P also failed to increase FSH secretion by the 
sheep cells. The most likely explanation for these varia- 
tions in P action appears to be species differences in 
gonadotroph function, a concept previously stated by 
Miller and Wu (1981) to explain sheep-rat differences 
in estrogenic regulation of FSH synthesis and secre- 
tion. 
The selective, P-induced increase in cell FSH levels 
observed in these cultures compromises investigation 
of secretagogue-stimulated LH/FSH secretion, espe- 
cially if one quantifies release simply by measuring the 
amount of hormone secreted into the medium. This 
approach would result in discrepancies, such as Pchronic 
suppressing LH release while increasing FSH secretion 
(Table 1; Drouin and Labrie, 19811, that are difficult to 
accommodate with current assumptions that GnRH 
stimulates the secretion of both hormones via a com- 
mon intracellular mechanism(s). However, by standard- 
izing gonadotropin secretion as the percentage of avail- 
able cellular stores that are released, one obtains simi- 
lar patterns for P modulation of LH and FSH release 
in response to GnRH, Ca2+ iontophores or protein 
kinase C activators. As discussed previously (Krey and 
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Kamel, 199Oc), the similarities of responses to GnRH 
and A23187 make it unlikely that P regulates GnRH 
action only via the modulation of GnRH receptor 
number. In contrast, PMA-stimulated LH and FSH 
release is increased by Pchronic treatment, a response 
that differs dramatically from that seen for GnRH and 
A23187; these differences raise questions about the 
role of protein kinase C activation in GnRH action, In 
any event, the observation that P induces parallel 
changes in the secretion of both gonadotropins, regard- 
less of secretagogue, suggests that P utilizes the same 
or common mechanisms to control LH and FSH secre- 
tion. 
Cellular LH and FSH stores consist of multiple 
immunoidentical isoforms that are separable by iso- 
electric focussing procedures and are characterized by 
differing bioactivities (Wakabayashi, 1977; Chappel et 
al., 1983; Hattori et al., 1983; Keel and Grotjan, 198.5; 
Green et al., 1986). In rodents, the distribution and 
secretion of LH isohormones appears to be under 
steroidal control, a hypothesis based on the observa- 
tions that, for secreted LH, steroid treatments influ- 
ences the B : I ratio of bioactivity to immunoactivity 
(Mukhopadhyay et al., 1979; Solano et al., 1980; Sar- 
danons et al., 1987). Although levels of bioactive FSH 
varied dramatically in the present studies depending on 
P treatment, these changes generally paralleled those 
for immunoreactive FSH and shifts in B : I were not 
observed. 
In summary, our findings indicate that P exerts 
multiple, direct actions on FSH synthesis and secre- 
tion. The timing of each of these actions in vitro is 
consistent with the hypothesis that they play important 
roles in vivo to ensure patterns of circulating FSH 
sufficient for folliculogenesis and ovulation to occur 
during the rat estrous cycle. In cultured cells, periovu- 
latory levels of P enhance GnRH-stimulated FSH se- 
cretion within 3 h, an interval consistent with a physio- 
logic role to maximize the size and duration of the 
preovulatory FSH surge on proestrous evening (Free- 
man, 1988). Within 6-9 h, the same progestin stimulus 
increases FSH synthesis in culture and, as a result, 
elevates the number of FSH molecules available for 
release in response to GnRH. A similar interval sepa- 
rates the initial P surge on proestrous evening and the 
secretion of the secondary FSH-only surge early on 
estrous morning (Freeman, 19881. This secondary surge 
influences the development of the next wave(s) of 
ovarian follicles (Greenwald and Terranova, 1988). The 
adenohypophysis is characterized by elevated FSH lev- 
els at the time of the secondary surge (Hasegawa et al., 
1981) and, as assessed in vitro, displays the highest 
basal rate of FSH release and the highest ratio of FSH 
to LH secreted in response to pulsatile GnRH admin- 
istration during proestrus or estrus (Fallest and 
Schwartz, 19901. Finally, after 2 12 h of exposure to P, 
the ability of GnRH to stimulate FSH secretion in 
cultured cells is suppressed; significantly, this time 
frame corresponds to estrus and diestrus, those days of 
the estrous cycle when serum FSH levels are at their 
nadir (Freeman, 1988). 
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